Viewing nowCombinationSitagliptin/Metformin Sustained Release Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.

MFDS item code 202201900 · Approved 2022.05.10 · Insurance code 642707310
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. The two ingredients, sitagliptin and metformin, work together to effectively manage blood glucose levels. This helps stabilize blood sugar levels and reduce the risk of complications. Therefore, this medication is used to enhance the treatment of patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken once daily with a meal, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is a total daily dose of sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. 2. Patients receiving metformin treatment: - The recommended initial dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is a total daily dose of sitagliptin 100 mg and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients taking immediate-release tablets at a dose of 850 mg or 1000 mg twice daily with their current metformin regimen may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is a total daily dose of sitagliptin 100 mg; the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1,000 mg daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine should be discontinued immediately.
This medication contains two components, sitagliptin and metformin, and is primarily used for the treatment of type 2 diabetes. First, while sitagliptin helps with blood sugar control, it can rarely cause severe allergic reactions. If symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur within 3 months of use, it is essential to stop using the medication immediately and consult a doctor. Also, sitagliptin can cause acute pancreatitis, so if symptoms like abdominal pain, vomiting, or severe indigestion occur, medication should be stopped immediately, and the patient should visit a hospital. Metformin has blood sugar-lowering effects but should not be administered to patients with severely impaired kidney function, dehydration, severe infections, or heart disease. Regular kidney function tests should be performed, particularly for these patients. This medication can pose a risk of lactic acidosis, a rare but life-threatening metabolic disorder. If symptoms such as sudden fatigue, muscle pain, difficulty breathing, abdominal pain, or confusion occur, the healthcare provider should be notified immediately. Excessive alcohol consumption can increase the risk of side effects from this medication, so alcohol should be avoided. Before surgery or radiological contrast examinations, patients should consult with their physician about temporarily discontinuing the medication and should resume it after kidney function has recovered. This medication should not be administered to pregnant or breastfeeding women, and its safety in individuals under 18 years of age has not been established. There is a risk of hypoglycemia while taking this medication, so especially if taken with other blood sugar-lowering agents, blood sugar levels should be checked frequently, and if unusual symptoms occur, the doctor should be consulted immediately. While taking this medication, regular blood tests and kidney function tests should be conducted to monitor for adverse reactions, and vitamin B12 levels may decrease, necessitating supplementation if required. Lastly, if an overdose of this medication is suspected, the patient should visit a hospital immediately for appropriate treatment, as some components may be removed by dialysis.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The recommended storage temperature is room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication for a longer period.
Bright blue, biconvex, oval-shaped sustained release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Dongwha Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.